GTEx Kidney 20-29 vs 50-59 Down (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GTEx Kidney 20-29 vs 50-59 Down.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GTEx Kidney 20-29 vs 50-59 Down.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GTEx Kidney 20-29 vs 50-59 Down.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GTEx Kidney 20-29 vs 50-59 Down.

Results found

Linked to

 

Label

Description

 

Gene

long intergenic non-protein coding RNA 511

Gene

lung cancer associated transcript 1

Gene

ubiquitin specific peptidase 32 pseudogene 1

Gene

FEZF1 antisense RNA 1

Gene

long intergenic non-protein coding RNA 1679

Gene

SLCO4A1 antisense RNA 1

Gene

BMS1 pseudogene 10

Gene

MAP3K2 divergent transcript

Gene

long intergenic non-protein coding RNA 1819

Gene

long intergenic non-protein coding RNA 1013

  • Gene

    long intergenic non-protein coding RNA 511


  • Gene

    lung cancer associated transcript 1


  • Gene

    ubiquitin specific peptidase 32 pseudogene 1


  • Gene

    FEZF1 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 1679


  • Gene

    SLCO4A1 antisense RNA 1


  • Gene

    BMS1 pseudogene 10


  • Gene

    MAP3K2 divergent transcript


  • Gene

    long intergenic non-protein coding RNA 1819


  • Gene

    long intergenic non-protein coding RNA 1013

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.